ABOUT THE RESEARCHER

OVERVIEW

Dr. Brennan-Krohn’s research involves the evaluation of antimicrobial combinations for synergistic activity against multidrug-resistant Gram-negative bacteria, specifically carbapenem-resistant Enterobacteriaceae (CRE). These pathogens, which are increasing in frequency worldwide, are very challenging to treat and tend to affect patients critically ill patients, in whom antibiotic selection may be complicated by factors including underlying illness and drug-drug interactions. Combination therapy is frequently used to treat such infections, with the goal of achieving synergistic activity between two drugs, but much remains to be understood about the mechanisms of action of antimicrobial combinations and about how to determine which combinations, if any, are likely to be effective against which pathogens. Dr. Brennan-Krohn’s research aims to identify promising combination regimens and to improve diagnostic methods for synergy testing.

BACKGROUND

Dr. Brennan-Krohn earned her BA in Classics from Brown University and her MD from Stanford University School of Medicine, then completed a Pediatrics residency and pediatric Infectious Diseases fellowship at Boston Children’s Hospital. She also completed a medical microbiology fellowship at Beth Israel Deaconess Medical Center and is a diplomate of the American Board of Medical Microbiology. Dr. Brennan-Krohn joined the division of Infectious Diseases as faculty in 2017. Her research is performed in the laboratory of Dr. James Kirby at Beth Israel Deaconess Medical Center.

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Reply to Humphries and Simner, "Verification Is an Integral Part of Antimicrobial Susceptibility Test Quality Assurance," and Wojewoda et al., "College of American Pathologists (CAP) Microbiology Committee Perspective: the Need for Verification Studies". J Clin Microbiol. 2020 03 25; 58(4). View abstract
  2. New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae. Transl Res. 2020 06; 220:14-32. View abstract
  3. Bringing Antimicrobial Susceptibility Testing for New Drugs into the Clinical Laboratory: Removing Obstacles in Our Fight against Multidrug-Resistant Pathogens. J Clin Microbiol. 2019 12; 57(12). View abstract
  4. Synergistic Combinations and Repurposed Antibiotics Active against the Pandrug-Resistant Klebsiella pneumoniae Nevada Strain. Antimicrob Agents Chemother. 2019 09; 63(9). View abstract
  5. When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing. Clin Lab Med. 2019 09; 39(3):345-358. View abstract
  6. Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method. J Vis Exp. 2019 04 18; (146). View abstract
  7. Synergistic Activity of Colistin-Containing Combinations against Colistin-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2018 10; 62(10). View abstract
  8. Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates. Diagn Microbiol Infect Dis. 2018 Oct; 92(2):168-171. View abstract
  9. Adherence to guidelines for testing and treatment of children with pharyngitis: a retrospective study. BMC Pediatr. 2018 02 09; 18(1):43. View abstract
  10. Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology. J Antimicrob Chemother. 2017 10 01; 72(10):2775-2781. View abstract
  11. Development of MAST: A Microscopy-Based Antimicrobial Susceptibility Testing Platform. SLAS Technol. 2017 12; 22(6):662-674. View abstract
  12. Arthroconidia in lung tissue: an unusual histopathological finding in pulmonary coccidioidomycosis. Hum Pathol. 2018 01; 71:55-59. View abstract
  13. The Poisoned Well: Enhancing the Predictive Value of Antimicrobial Susceptibility Testing in the Era of Multidrug Resistance. J Clin Microbiol. 2017 08; 55(8):2304-2308. View abstract
  14. Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method. J Clin Microbiol. 2017 02; 55(2):470-478. View abstract
  15. The Brief Case: Safe To Go Back in the Water? Vibrio parahaemolyticus Wound Infection Associated with Brackish Water. J Clin Microbiol. 2016 06; 54(6):1414-1415. View abstract
  16. Closing the Brief Case: Safe To Go Back in the Water? Vibrio parahaemolyticus Wound Infection Associated with Brackish Water. J Clin Microbiol. 2016 06; 54(6):1672. View abstract
  17. Glial vascular degeneration in CADASIL. J Alzheimers Dis. 2010; 21(4):1393-402. View abstract
  18. Frontal white matter integrity in borderline personality disorder with self-injurious behavior. J Neuropsychiatry Clin Neurosci. 2007; 19(4):383-90. View abstract
  19. White matter integrity in kleptomania: a pilot study. Psychiatry Res. 2006 Oct 30; 147(2-3):233-7. View abstract